Development and performance of a formalin-damaged multiplexed DNA tumor mutation FFPE reference material

Determining and using the most effective and safest treatment is of great importance in cancer disease management. Recently, a potential biomarker has been identified in immunotherapy: tumor mutational burden (TMB), an assessment of the number of relevant mutations in a tumor.

Reference materials that closely mimic the damage profile of patient FFPE samples are lacking. We have developed a formalin-damaged, multiplexed biosynthetic FFPE reference material to mimic the damage found in patient samples to create a more patient-like control that can be used to assess the entire tumor profiling workflow. We compared its performance in downstream assays to that of material with less damage. Download this free poster to learn about development and performance of a formalin-damaged multiplexed DNA tumor mutation FFPE reference material.